TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1299486

Group type: EXPERIMENTAL
Intervention: Low intensity exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both exercise intensities
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High intensity exercise following a meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low intensity exercise following a meal
Number of subjects: 16
Study: 6240537

Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 50

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gold or D-penicillamine in remission
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: D-penicillamine toxicity
Number of subjects: 50
Study: 31364269

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saxagliptin (5 mg/day)
Number of subjects: 0
Study: 28202270

Group type: EXPERIMENTAL
Intervention: 25% glucose solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fructose solution
Number of subjects: 18
Study: 26476459

Group type: EXPERIMENTAL
Intervention: Zonisamide + varenicline
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo + varenicline
Number of subjects: 74
Study: 25305000

Group type: EXPERIMENTAL
Intervention: M72/AS01 (1 or 2 doses)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Meningitis vaccine or EPI vaccines alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: M72/AS01
Number of subjects: 300
Study: 21093072

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study: 19602614

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Healthy Controls (C)
Number of subjects: 287
Study: 17643582

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 15904

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 15904
Study: 15863409

Group type: EXPERIMENTAL
Intervention: MMSE cut-off of 23/24
Number of subjects: 15051

Group type: EXPERIMENTAL
Intervention: MMSE cut-off of 17/18
Number of subjects: 15051

Group type: EXPERIMENTAL
Intervention: MMSE 23/24
Number of subjects: 15051

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 15051
Study: 12043780

Group type: EXPERIMENTAL
Intervention: Bilateral TKR
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Unilateral TKR
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Cemented replacement
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Cementless replacement
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Follow-up venograms at six months
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Pulmonary embolism assessment
Number of subjects: 227
Study: 10446831

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fentanyl and midazolam
Number of subjects: 21
Study: 7597610

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 38
Study: 1866817

Group type: EXPERIMENTAL
Intervention: Chloramphenicol ointment and an eye patch for six hours followed by chloramphenicol eyedrops six times a day for six days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloramphenicol ointment and double eye patches for twenty-four hours as the only treatment.
Number of subjects: 40
Study: 6810423

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both age groups (sodium cromoglycate and placebo)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nebulised water (placebo response)
Number of subjects: 44
Study: 31058947

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including case management, reminders, a roadmap and checklist for the therapeutic plan, educational materials, and periodic audit and feedback reports.
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 1624

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention
Number of subjects: 1624
Study: 29934526

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 0
Study: 27111192

Group type: EXPERIMENTAL
Intervention: TC‐3 gel + 200 U OnabotA (Group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: DMSO (Group D)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo, Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: TC‐3 gel + 200 U OnabotA + DMSO (Group C)
Number of subjects: 39
Study: 25092553

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Segmental Exercises (SE)
Number of subjects: 30
Study: 22176488

Group type: EXPERIMENTAL
Intervention: Rest breaks according to perceived decrements in postural stability
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Static pure tone auditory stimulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moving conversation auditory stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 16
Study: 20857370

Group type: EXPERIMENTAL
Intervention: Routine disinfection of floors after every surgical procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disinfection of floors only in case of visible contamination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (routine disinfection and disinfection after visible contamination)
Number of subjects: 0
Study: 17990225

Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (eflornithine 400 mg/kg per day IV every 12 h for 7 days + nifurtimox 15 mg/kg per day orally every 8 h for 10 days)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Eflornithine alone (400 mg/kg per day IV every 6 h for 14 days)
Number of subjects: 103
Study: 15022037

Group type: EXPERIMENTAL
Intervention: 3D‐LSGA based measurements in treated group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 12926186

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with Olea europaea extract, administered preseasonally with a maintenance dose 3.8 times higher than conventional treatments, reaching a maximal dose of 75 BU (45 micrograms Ole e 1).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SIT treatment).
Number of subjects: 0
Study: 9609132

Group type: EXPERIMENTAL
Intervention: 60 mg/day Carbimazole for 12 months (Group 1, n = 23)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 45 mg/day for the first month, 30 mg/day for the second, and 20 mg/day for the remaining 10 months of Carbimazole (Group 2, n = 34)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 57
Study: 9815961

Group type: EXPERIMENTAL
Intervention: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. twice weekly for 8 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo liposomes (lipid equivalent), twice weekly for 8 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. once or twice weekly for 8 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (CDDP), 70 mg/m2 i.v. every 21 days x 4
Number of subjects: 104
Study: 2677863

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 106
Study: 375153

Group type: EXPERIMENTAL
Intervention: promethazine‐A.P.C. combination
Number of subjects: 149
Study: 31723049

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) procedures performed
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Mean MT direct time burden during each 24-hour call
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Percentage of consultations for thrombectomy based on time of day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: MT procedural volumes
Number of subjects: 166
Study: 31050167

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS targeting the left DLPFC (10 Hz, 2000 pulses over 20 minutes, 8 sessions over 4 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS targeting the left DLPFC
Number of subjects: 45
Study: 28779937

Group type: EXPERIMENTAL
Intervention: Yoga Training Program (YTP) - 8 weeks, 24 sessions
Number of subjects: 29
Study: 26189560

Group type: EXPERIMENTAL
Intervention: GEMOX plus erlotinib
Number of subjects: 103

Group type: COMPARATOR
Intervention: GEMOX
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: GEMOX with or without erlotinib
Number of subjects: 103
Study: 23659338

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation (500 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21805296

Group type: EXPERIMENTAL
Intervention: Yiqi Bufei Recipe (YBR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with normal lung function
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive control group (PI without treatment)
Number of subjects: 60
Study: 19136216

Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 21
Study: 17223420

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention plus intensive, guideline-driven medical therapy
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2287
Study: 15378098

Group type: EXPERIMENTAL
Intervention: Seated exercise program (three times per week for four cycles of chemotherapy)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Seated exercise program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no seated exercise)
Number of subjects: 38
Study: 11469436

Group type: EXPERIMENTAL
Intervention: P2 of 2 msec
Number of subjects: 62

Group type: COMPARATOR
Intervention: P2 of 5 msec
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: P2 of 2 msec with amiodarone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: P2 of 2 msec with d,l-sotalol
Number of subjects: 62
Study: 10451971

Group type: EXPERIMENTAL
Intervention: Foldable intraocular lens (IOL) implantation after phacoemulsification
Number of subjects: 49
Study: 7616557

Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum) 7.5 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Promethazine (Phenergan) 25 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Droperidol 2.5 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 3283661

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin 1500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29371075

Group type: EXPERIMENTAL
Intervention: COLD water (0.4±0.4°C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: COOL water (7.3±0.8°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: TEMP water (22.1±1.2°C)
Number of subjects: 12
Study: 27078022

Group type: EXPERIMENTAL
Intervention: Neratinib plus Paclitaxel
Number of subjects: 479

Group type: COMPARATOR
Intervention: Trastuzumab plus Paclitaxel
Number of subjects: 479
Study: 25587825

Group type: EXPERIMENTAL
Intervention: Mobilisation to the toilet (Group I)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Use of a bedpan or urinal in the bed (Group C)
Number of subjects: 152
Study: 23660628

Group type: EXPERIMENTAL
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-CR-predicted patients
Number of subjects: 112
Study: 20937993

Group type: EXPERIMENTAL
Intervention: Filtered air
Number of subjects: 126

Group type: COMPARATOR
Intervention: Perfluoropropane gas
Number of subjects: 126
Study: 18070831

Group type: EXPERIMENTAL
Intervention: Continuous infusion of temocillin (4 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Twice daily administration of temocillin (2 g every 12 h)
Number of subjects: 12
Study: 16571276

Group type: EXPERIMENTAL
Intervention: ZY‐4
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 12711383

Group type: EXPERIMENTAL
Intervention: Xylitol‐ and fluoride‐containing dentifrice (XF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Non‐xylitol‐ and fluoride‐containing dentifrice (F)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non‐xylitol‐ and non‐fluoride‐containing dentifrice (NonX‐NonF)
Number of subjects: 6
Study: 15101878

Group type: EXPERIMENTAL
Intervention: Telephone-based pharmaceutical care program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Routine pharmaceutical care (control)
Number of subjects: 107
Study: 9365750

Group type: EXPERIMENTAL
Intervention: Multimedia textbook (MMTB)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Printed textbook
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 1559428

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sudden withdrawal
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 3936089

Group type: EXPERIMENTAL
Intervention: Pre-abstinence smoking motivation (dependent smoking subscale)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pre-abstinence smoking motivation (indulgent smoking subscale)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pre-abstinence plasma nicotine concentration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Expired-air CO
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Usual daily cigarette consumption
Number of subjects: 29
Study: 31829276

Group type: EXPERIMENTAL
Intervention: Real acuTENS treatment for 45 min once a day for five consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acuTENS treatment for 45 min once a day for five consecutive days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Real acuTENS treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acuTENS treatment
Number of subjects: 60
Study: 30342553

Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 525

Group type: COMPARATOR
Intervention: CD34+
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Adverse cytogenetic
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Unrelated donor
Number of subjects: 525

Group type: COMPARATOR
Intervention: ATG vs CD34+
Number of subjects: 525
Study: 26716896

Group type: EXPERIMENTAL
Intervention: ADV‐TK
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ADV‐TK (subgroup of glioblastoma)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 24815889

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 27.5 μg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22688444

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg (K1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 3 mg/kg (K2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline 1 drop/5 kg
Number of subjects: 120
Study: 20660044

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Melatonin profile
Number of subjects: 6
Study: 18554819

Group type: EXPERIMENTAL
Intervention: Electronic personalised feedback and social norms information on drinking behaviour (12-week duration)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Electronic personalised feedback and social norms information
Number of subjects: 506
Study: 16159570

Group type: COMPARATOR
Intervention: Huobahuagen Tablets (5 tablets po t.i.d.)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 to 300 mg po q.d.)
Number of subjects: 62
Study: 11943447

Group type: EXPERIMENTAL
Intervention: Focus group-developed consent document
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Investigator-developed consent document
Number of subjects: 1092
Study: 10067004

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment of relatives of patients with schizophrenia
Number of subjects: 126
Study: 8826921

Group type: EXPERIMENTAL
Intervention: Leuprolide-flutamide androgen inhibition therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Nonhormonally treated prostates
Number of subjects: 173
Study: 2147599

Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered orally for 6 months (1600-2400 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by intravenous infusion (500-1000 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by intramuscular injection (100-200 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by mouth (1600-2400 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP)
Number of subjects: 27
Study: 6105342

Group type: EXPERIMENTAL
Intervention: Propranolol (continuous, oral administration, dosage not specified)
Number of subjects: 0
Study: 31856425

Group type: EXPERIMENTAL
Intervention: atomoxetine 18 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: midodrine 5 mg twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: combination treatment (atomoxetine and midodrine)
Number of subjects: 50
Study: 31156144

Group type: EXPERIMENTAL
Intervention: Kuan-Sin-Yin treatment (Group K)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No Kuan-Sin-Yin treatment (Group NK)
Number of subjects: 17
Study: 28984747

Group type: EXPERIMENTAL
Intervention: 30-day diazepam treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10-day diazepam treatment
Number of subjects: 26
Study: 25352438

Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED2; -22 ± 3%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED3; -42 ± 3%)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exercising control (EXCON)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED1; -8 ± 2%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Average percent energy deficit
Number of subjects: 34
Study: 23548195

Group type: EXPERIMENTAL
Intervention: Motivational interviewing pre-pain rehabilitation intervention (MIP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 160
Study: 22289549

Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: 20 mg/day atorvastatin
Number of subjects: 36
Study: 19349559

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1108
Study: 16432086

Group type: EXPERIMENTAL
Intervention: Bedside tests (7-variable clinical model, D-dimer test, alveolar dead-space fraction)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Ventilation-perfusion (V/Q) scan
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Bedside tests (with at least 2 negative results)
Number of subjects: 398

Group type: COMPARATOR
Intervention: 7-variable clinical model and D-dimer test
Number of subjects: 398
Study: 15134181

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 142
Study: 11394467

Group type: EXPERIMENTAL
Intervention: Device for measuring gripping forces and applied moments during hand tool use
Number of subjects: 0
Study: 9608414

Group type: EXPERIMENTAL
Intervention: 15 mg D-cycloserine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher medication dosage or long-term treatment
Number of subjects: 0
Study: 8080299

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C and/or 5-fluorouracil
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1177
Study: 2513173

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 100 micrograms
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 4448416

Group type: EXPERIMENTAL
Intervention: Concentrate alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Concentrate plus heparin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 9
Study: 31102457

Group type: EXPERIMENTAL
Intervention: sildenafil (PDE5 inhibitor) for 8 weeks in mice
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: sildenafil (PDE5 inhibitor) for 4 weeks in humans
Number of subjects: 2

Group type: COMPARATOR
Intervention: vehicle (control) for 8 weeks in mice
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo for 4 weeks in humans
Number of subjects: 2
Study: 28077344

Group type: EXPERIMENTAL
Intervention: H‐FABP in DKA patients at presentation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: H‐FABP in DKA patients after acidosis correction (at hour 36)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Troponin I and CK‐MB levels in all groups
Number of subjects: 75
Study: 25227729

Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse PM (CAP) (76.2 ± 51.5 μg/m(3))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32